GeoVax Labs, Inc. Logo

GeoVax Labs, Inc.

GOVXW

(1.2)
Stock Price

0,19 USD

-145.18% ROA

-187.46% ROE

-0.43x PER

Market Cap.

11.251.980,00 USD

0% DER

0% Yield

0% NPM

GeoVax Labs, Inc. Stock Analysis

GeoVax Labs, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

GeoVax Labs, Inc. Fundamental Stock Analysis
# Analysis Rating
1 PBV

With a remarkably low PBV ratio (0.83x), the stock offers substantial upside potential at a bargain price.

2 DER

The stock has a low debt to equity ratio (0%), which means it has a small amount of debt compared to the ownership it holds

3 Graham Number

The Graham number analysis indicates that this company's stock price is likely undervalued, raising prospects for a favorable investment opportunity.

4 ROA

The stock's ROA (-89.78%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

5 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

6 Net Profit Growth

This company's net profit has remained stagnant over the past five years, indicating a lack of growth and making it a less favorable investment option.

7 Assets Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

8 Dividend Growth

The company's dividend growth has remained flat for the past three years, offering no indication of improved returns and making it a less advantageous investment opportunity.

9 Dividend

The company's decision to withhold dividends for three years raises questions about its ability to generate consistent returns.

10 Buffet Intrinsic Value

The company's stock shows signs of being overvalued (0) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.

11 ROE

Negative ROE (-77.54%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

GeoVax Labs, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

GeoVax Labs, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Sell
3 RSI Hold
4 Stoch RSI Sell

GeoVax Labs, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

GeoVax Labs, Inc. Revenue
Year Revenue Growth
1996 93.947
1997 2.730.035 96.56%
1998 5.367.514 49.14%
1999 2.279.058 -135.51%
2000 859.837 -165.06%
2001 2.620.207 67.18%
2002 180.237 -1353.76%
2003 0 0%
2004 0 0%
2005 0 0%
2006 852.905 100%
2007 237.004 -259.87%
2008 2.910.170 91.86%
2009 3.668.195 20.66%
2010 5.185.257 29.26%
2011 4.899.885 -5.82%
2012 2.657.000 -84.41%
2013 2.417.550 -9.9%
2014 882.956 -173.8%
2015 428.081 -106.26%
2016 828.918 48.36%
2017 1.075.270 22.91%
2018 963.000 -11.66%
2019 1.175.896 18.11%
2020 1.823.000 35.5%
2021 385.000 -373.51%
2022 81.000 -375.31%
2023 0 0%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

GeoVax Labs, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
1996 76.711
1997 827.843 90.73%
1998 1.576.477 47.49%
1999 510.287 -208.94%
2000 1.472.093 65.34%
2001 2.434.006 39.52%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 665.863 100%
2007 1.757.125 62.1%
2008 3.741.489 53.04%
2009 4.068.682 8.04%
2010 4.793.956 15.13%
2011 4.276.375 -12.1%
2012 3.043.000 -40.53%
2013 2.914.878 -4.4%
2014 1.812.969 -60.78%
2015 1.693.102 -7.08%
2016 1.970.859 14.09%
2017 2.017.350 2.3%
2018 1.879.000 -7.36%
2019 1.910.715 1.66%
2020 2.444.000 21.82%
2021 15.554.000 84.29%
2022 9.123.000 -70.49%
2023 27.791.916 67.17%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

GeoVax Labs, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
1996 0
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 843.335 100%
2007 0 0%
2008 2.970.068 100%
2009 2.914.845 -1.89%
2010 3.162.134 7.82%
2011 2.972.555.000 99.89%
2012 1.753.000 -169469.59%
2013 1.792.160 2.19%
2014 1.807.605 0.85%
2015 1.429.731 -26.43%
2016 2.131.426 32.92%
2017 1.232.368 -72.95%
2018 1.647.000 25.17%
2019 1.637.674 -0.57%
2020 2.196.000 25.42%
2021 3.577.000 38.61%
2022 4.987.000 28.27%
2023 6.607.100 24.52%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

GeoVax Labs, Inc. EBITDA
Year EBITDA Growth
1996 -1.235.846
1997 -3.834.431 67.77%
1998 -4.921.579 22.09%
1999 -6.136.309 19.8%
2000 -6.703.234 8.46%
2001 -11.573.563 42.08%
2002 180.237 6521.3%
2003 -653.851 127.57%
2004 -1.506.509 56.6%
2005 -405.218 -271.78%
2006 -607.198 33.26%
2007 -4.249.842 85.71%
2008 -3.740.373 -13.62%
2009 -3.225.556 -15.96%
2010 -2.651.060 -21.67%
2011 -2.240.028 -18.35%
2012 -2.139.000 -4.72%
2013 -2.206.081 3.04%
2014 -2.668.581 17.33%
2015 -2.665.817 -0.1%
2016 -3.244.587 17.84%
2017 -2.146.421 -51.16%
2018 -2.563.000 16.25%
2019 -2.357.784 -8.7%
2020 -2.817.000 16.3%
2021 -18.746.000 84.97%
2022 -14.029.000 -33.62%
2023 -34.329.740 59.13%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

GeoVax Labs, Inc. Gross Profit
Year Gross Profit Growth
1996 -185.285
1997 -1.615.280 88.53%
1998 -390.375 -313.78%
1999 -2.554.543 84.72%
2000 -2.015.790 -26.73%
2001 -124.792 -1515.32%
2002 180.237 169.24%
2003 0 0%
2004 0 0%
2005 0 0%
2006 852.905 100%
2007 237.004 -259.87%
2008 2.910.170 91.86%
2009 3.668.195 20.66%
2010 5.185.257 29.26%
2011 4.899.885 -5.82%
2012 2.657.000 -84.41%
2013 2.417.550 -9.9%
2014 882.956 -173.8%
2015 428.081 -106.26%
2016 828.918 48.36%
2017 1.075.270 22.91%
2018 -915.652 217.43%
2019 1.175.896 177.87%
2020 1.823.000 35.5%
2021 385.000 -373.51%
2022 81.000 -375.31%
2023 0 0%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

GeoVax Labs, Inc. Net Profit
Year Net Profit Growth
1996 36.668.669
1997 -3.988.017 1019.47%
1998 -6.131.557 34.96%
1999 -9.306.304 34.11%
2000 -8.817.362 -5.55%
2001 -13.252.360 33.47%
2002 -618.137 -2043.92%
2003 -3.077.080 79.91%
2004 -2.207.806 -39.37%
2005 -1.408.534 -56.74%
2006 -584.166 -141.12%
2007 -4.241.796 86.23%
2008 -3.728.187 -13.78%
2009 -3.284.252 -13.52%
2010 -2.747.328 -19.54%
2011 -2.346.826 -17.07%
2012 -2.135.000 -9.92%
2013 -2.284.943 6.56%
2014 -2.733.555 16.41%
2015 -2.689.287 -1.65%
2016 -3.271.701 17.8%
2017 -2.170.162 -50.76%
2018 -2.560.000 15.23%
2019 -2.375.124 -7.78%
2020 -2.938.344 19.17%
2021 -18.531.479 84.14%
2022 -14.014.561 -32.23%
2023 -33.635.272 58.33%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

GeoVax Labs, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1996 79
1997 -9 1087.5%
1998 -13 38.46%
1999 -20 35%
2000 -19 -5.26%
2001 -29 32.14%
2002 -1 -2700%
2003 -7 83.33%
2004 -5 -50%
2005 -3 -33.33%
2006 -1 -200%
2007 -9 88.89%
2008 -8 -12.5%
2009 -7 -14.29%
2010 -6 -40%
2011 -5 0%
2012 -2.135.000 100%
2013 -2.284.943 6.56%
2014 -2.733.555 16.41%
2015 -2.689.287 -1.65%
2016 -1.635.851 -64.4%
2017 -434.032 -276.9%
2018 -256.000 -69.54%
2019 -158 -161925.32%
2020 -2 -7800%
2021 -3 33.33%
2022 -1 0%
2023 -1 100%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

GeoVax Labs, Inc. Free Cashflow
Year Free Cashflow Growth
1996 -1.246.466
1997 -2.648.879 52.94%
1998 -6.419.721 58.74%
1999 -4.483.198 -43.2%
2000 -6.329.553 29.17%
2001 -4.874.305 -29.86%
2003 288.308 1790.66%
2004 -1.234.661 123.35%
2005 -1.426.441 13.44%
2006 -1.397.407 -2.08%
2007 -3.265.743 57.21%
2008 -2.467.717 -32.34%
2009 -1.695.396 -45.55%
2010 -2.011.875 15.73%
2011 -315.517 -537.64%
2012 -2.441.247 87.08%
2013 -1.781.195 -37.06%
2014 -2.285.610 22.07%
2015 -2.721.113 16%
2016 -17.796.119 84.71%
2017 -1.692.814 -951.27%
2018 -1.543.026 -9.71%
2019 -1.406.103 -9.74%
2020 -2.907.361 51.64%
2021 -11.244.138 74.14%
2022 -19.164.466 41.33%
2023 -5.101.870 -275.64%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

GeoVax Labs, Inc. Operating Cashflow
Year Operating Cashflow Growth
1996 -1.165.256
1997 -2.446.914 52.38%
1998 -5.351.143 54.27%
1999 -4.457.518 -20.05%
2000 -6.327.358 29.55%
2001 -4.213.022 -50.19%
2003 288.308 1561.29%
2004 -1.234.661 123.35%
2005 -1.426.441 13.44%
2006 -1.327.941 -7.42%
2007 -3.265.743 59.34%
2008 -2.367.886 -37.92%
2009 -1.425.150 -66.15%
2010 -2.007.169 29%
2011 -303.621 -561.08%
2012 -2.441.247 87.56%
2013 -1.694.592 -44.06%
2014 -2.250.107 24.69%
2015 -2.705.263 16.82%
2016 -1.946.119 -39.01%
2017 -1.688.464 -15.26%
2018 -1.543.026 -9.43%
2019 -1.398.497 -10.33%
2020 -2.750.570 49.16%
2021 -11.196.420 75.43%
2022 -19.030.208 41.17%
2023 -5.095.678 -273.46%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

GeoVax Labs, Inc. Capital Expenditure
Year Capital Expenditure Growth
1996 81.210
1997 201.965 59.79%
1998 1.068.578 81.1%
1999 25.680 -4061.13%
2000 2.195 -1069.93%
2001 661.283 99.67%
2003 0 0%
2004 0 0%
2005 0 0%
2006 69.466 100%
2007 0 0%
2008 99.831 100%
2009 270.246 63.06%
2010 4.706 -5642.58%
2011 11.896 60.44%
2012 0 0%
2013 86.603 100%
2014 35.503 -143.93%
2015 15.850 -123.99%
2016 15.850.000 99.9%
2017 4.350 -364267.82%
2018 0 0%
2019 7.606 100%
2020 156.791 95.15%
2021 47.718 -228.58%
2022 134.258 64.46%
2023 6.192 -2068.25%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

GeoVax Labs, Inc. Equity
Year Equity Growth
1996 3.092.900
1997 5.675.595 45.51%
1998 2.885.228 -96.71%
1999 552.344 -422.36%
2000 10.520.864 94.75%
2001 2.048.891 -413.49%
2002 -639.393 420.44%
2003 -3.817.212 83.25%
2004 -4.946.185 22.83%
2005 -5.715.192 13.46%
2006 2.203.216 359.4%
2007 2.647.866 16.79%
2008 2.709.819 2.29%
2009 3.744.232 27.63%
2010 1.836.226 -103.91%
2011 703.607 -160.97%
2012 1.150.935 38.87%
2013 2.527.227 54.46%
2014 1.146.175 -120.49%
2015 1.204.603 4.85%
2016 240.370 -401.15%
2017 -321.057 174.87%
2018 -1.022.000 68.59%
2019 -1.574.556 35.09%
2020 9.569.000 116.45%
2021 4.362.000 -119.37%
2022 26.600.000 83.6%
2023 9.119.346 -191.69%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

GeoVax Labs, Inc. Assets
Year Assets Growth
1996 3.402.860
1997 7.269.136 53.19%
1998 6.719.635 -8.18%
1999 3.372.154 -99.27%
2000 11.160.777 69.79%
2001 3.917.424 -184.9%
2002 371.026 -955.84%
2003 172.197 -115.47%
2004 19.161 -798.68%
2005 78.381 75.55%
2006 2.396.330 96.73%
2007 3.246.404 26.19%
2008 3.056.241 -6.22%
2009 4.315.597 29.18%
2010 2.357.834 -83.03%
2011 1.645.142 -43.32%
2012 1.477.970 -11.31%
2013 2.839.576 47.95%
2014 1.333.198 -112.99%
2015 1.331.593 -0.12%
2016 610.217 -118.22%
2017 490.235 -24.47%
2018 642.000 23.64%
2019 468.880 -36.92%
2020 10.394.000 95.49%
2021 11.797.000 11.89%
2022 31.348.000 62.37%
2023 16.201.031 -93.49%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

GeoVax Labs, Inc. Liabilities
Year Liabilities Growth
1996 309.960
1997 1.593.541 80.55%
1998 3.834.407 58.44%
1999 2.819.810 -35.98%
2000 639.913 -340.66%
2001 1.868.533 65.75%
2002 1.010.419 -84.93%
2003 3.989.409 74.67%
2004 4.965.346 19.65%
2005 5.793.573 14.3%
2006 193.114 -2900.08%
2007 598.538 67.74%
2008 346.422 -72.78%
2009 571.365 39.37%
2010 521.608 -9.54%
2011 941.535 44.6%
2012 327.035 -187.9%
2013 312.349 -4.7%
2014 187.023 -67.01%
2015 126.990 -47.27%
2016 369.847 65.66%
2017 811.292 54.41%
2018 1.664.000 51.24%
2019 2.043.436 18.57%
2020 825.000 -147.69%
2021 7.435.000 88.9%
2022 4.748.000 -56.59%
2023 7.081.685 32.95%

GeoVax Labs, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
-0
Net Income per Share
-0.89
Price to Earning Ratio
-0.43x
Price To Sales Ratio
-138.02x
POCF Ratio
-0.46
PFCF Ratio
-0.51
Price to Book Ratio
1.1
EV to Sales
17.6
EV Over EBITDA
0.06
EV to Operating CashFlow
0.07
EV to FreeCashFlow
0.07
Earnings Yield
-2.34
FreeCashFlow Yield
-1.94
Market Cap
0,01 Bil.
Enterprise Value
0,00 Bil.
Graham Number
2.62
Graham NetNet
0.21

Income Statement Metrics

Net Income per Share
-0.89
Income Quality
0.92
ROE
-1.24
Return On Assets
-2.77
Return On Capital Employed
-4.64
Net Income per EBT
0.99
EBT Per Ebit
0.97
Ebit per Revenue
0
Effective Tax Rate
0

Margins

Sales, General, & Administrative to Revenue
-75.86
Research & Developement to Revenue
-223.87
Stock Based Compensation to Revenue
-13.06
Gross Profit Margin
0
Operating Profit Margin
0
Pretax Profit Margin
0
Net Profit Margin
0

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.83
Free CashFlow per Share
-0.82
Capex to Operating CashFlow
-0
Capex to Revenue
-1.28
Capex to Depreciation
1.58
Return on Invested Capital
-2.65
Return on Tangible Assets
-1.45
Days Sales Outstanding
0
Days Payables Outstanding
18863.34
Days of Inventory on Hand
0
Receivables Turnover
0
Payables Turnover
0.02
Inventory Turnover
0
Capex per Share
0

Balance Sheet

Cash per Share
0,48
Book Value per Share
0,34
Tangible Book Value per Share
0.34
Shareholders Equity per Share
0.34
Interest Debt per Share
-0.01
Debt to Equity
0
Debt to Assets
0
Net Debt to EBITDA
0.52
Current Ratio
2.09
Tangible Asset Value
0,01 Bil.
Net Current Asset Value
0,01 Bil.
Invested Capital
0
Working Capital
0,01 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
0
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

GeoVax Labs, Inc. Dividends
Year Dividends Growth

GeoVax Labs, Inc. Profile

About GeoVax Labs, Inc.

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is also developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; GEO-EM01 for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. GeoVax Labs, Inc. has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.

CEO
Mr. David Alan Dodd
Employee
17
Address
1900 Lake Park Drive
Smyrna, 30080

GeoVax Labs, Inc. Executives & BODs

GeoVax Labs, Inc. Executives & BODs
# Name Age
1 Mr. David Alan Dodd
Chairman, President & Chief Executive Officer
70
2 Dr. Mark J. Newman Ph.D.
Chief Scientific Officer
70
3 Dr. Kelly T. McKee Jr., M.D., M.P.H.
Chief Medical Officer
70
4 Dr. John W. Sharkey Ph.D.
Vice President of Business Development
70
5 Dr. Harriet Latham Robinson Ph.D.
Founder, Chief Scientific Officer Emeritus & Member of Scientific Advisory Board
70
6 Jeffrey Welch
Head of Process Development & Manufacturing Operations
70

GeoVax Labs, Inc. Competitors